Viatris bets $350 million upfront on two late-stage drugs from Idorsia
28 Feb 2024
Phase 3License out/inImmunotherapyPhase 2
Viatris will pay $350 million upfront for rights to two of Idorsia’s experimental late-stage drugs, including the P2Y12 inhibitor selatogrelP2Y12 inhibitor selatogrel for patients with a history of acute myocardial infarction (AMI). The second compound is the immunology asset cenerimod, which is being developed for the treatment of systemic lupus erythematosus (SLE).
Jean-Paul Clozel, chief executive of Idorsia, explained that the “global collaboration allows us to share the costs of the ongoing Phase III programmes whilst retaining long-term shareholder value, by sharing the rewards for success through the milestones and royalties." The agreement also gives Viatris a right of first refusal and a right of first negotiation for certain other assets in Idorsia's pipeline.
Selatogrel is intended to be self-administered subcutaneously via an autoinjector and has the potential to protect heart muscle in the very early phase of an AMI. Idorsia is currently recruiting patients in the Phase III SOS-AMI study to assess selatogrel when self-administered upon the occurrence of symptoms suggestive of AMI.
Meanwhile, the S1P1 receptor modulator cenerimod is being investigated in two late-stage trials in the OPUS programme, which kicked off at the end of 2022. The studies are evaluating the oral once-daily tablet in adults with moderate-to-severe SLE on top of background therapy. Viatris suggested that cenerimod also has potential across multiple autoimmune diseases and could be a “cornerstone” of its immunology platform.
Viatris CEO Scott Smith said “in addition to continuing to develop the three core therapeutic areas that we identified—ophthalmology, dermatology and GI—we are also going to be opportunistic in seeking out assets that we believe fit our company well and have the potential to contribute significantly to our future revenue growth.”
More to follow.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Targets
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.